[
    [
        {
            "time": "",
            "original_text": "医药界的“小恒瑞”！创新药隐形冠军，毛利率比茅台、恒瑞还高",
            "features": {
                "keywords": [
                    "医药",
                    "创新药",
                    "毛利率",
                    "恒瑞",
                    "茅台"
                ],
                "sentiment_score": 0.9,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": ""
            },
            "scores": {
                "News_content": "医药界的“小恒瑞”！创新药隐形冠军，毛利率比茅台、恒瑞还高",
                "Correlation": 9,
                "Sentiment": 8,
                "Importance": 7,
                "Impact": 7,
                "Duration": 6,
                "Entity_Density": 6,
                "Market_Scope": 5,
                "Time_Proximity": 5,
                "Headline_Structure": 9,
                "Source_Recency": 6
            }
        },
        {
            "time": "",
            "original_text": "创纪录！人民金融·创新药指数涨2.88%！16个品种获批临床，贝达药业进军双抗，多款创新药取得重大进展",
            "features": {
                "keywords": [
                    "创新药指数",
                    "涨2.88%",
                    "贝达药业",
                    "双抗",
                    "临床",
                    "重大进展"
                ],
                "sentiment_score": 0.85,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "创纪录！人民金融·创新药指数涨2.88%！16个品种获批临床，贝达药业进军双抗，多款创新药取得重大进展",
                "Correlation": 9,
                "Sentiment": 9,
                "Importance": 8,
                "Impact": 8,
                "Duration": 7,
                "Entity_Density": 7,
                "Market_Scope": 6,
                "Time_Proximity": 7,
                "Headline_Structure": 9,
                "Source_Recency": 8
            }
        },
        {
            "time": "",
            "original_text": "创新药板块热度不减，双鹭、海思科、丽珠、人福、贝达、康龙化成均大涨",
            "features": {
                "keywords": [
                    "创新药",
                    "双鹭",
                    "海思科",
                    "丽珠",
                    "人福",
                    "贝达",
                    "康龙化成",
                    "大涨"
                ],
                "sentiment_score": 0.8,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "创新药板块热度不减，双鹭、海思科、丽珠、人福、贝达、康龙化成均大涨",
                "Correlation": 8,
                "Sentiment": 8,
                "Importance": 7,
                "Impact": 7,
                "Duration": 5,
                "Entity_Density": 8,
                "Market_Scope": 8,
                "Time_Proximity": 6,
                "Headline_Structure": 7,
                "Source_Recency": 7
            }
        },
        {
            "time": "",
            "original_text": "国金证券上调贝达药业评级至买入：多款产品即将上市，自主研发逐步验证，目标价145元",
            "features": {
                "keywords": [
                    "国金证券",
                    "贝达药业",
                    "买入",
                    "产品上市",
                    "自主研发",
                    "目标价145元"
                ],
                "sentiment_score": 0.9,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": ""
            },
            "scores": {
                "News_content": "国金证券上调贝达药业评级至买入：多款产品即将上市，自主研发逐步验证，目标价145元",
                "Correlation": 10,
                "Sentiment": 9,
                "Importance": 9,
                "Impact": 9,
                "Duration": 8,
                "Entity_Density": 9,
                "Market_Scope": 4,
                "Time_Proximity": 8,
                "Headline_Structure": 8,
                "Source_Recency": 9
            }
        }
    ]
]